Big Pharma spends big on doctors, reaps profits

By Esther Han
Updated January 26 2018 - 9:53am, first published January 14 2018 - 9:13pm
The logo of AstraZeneca is seen on a medication package in a pharmacy in London April 28, 2014. U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid battle for Britain's AstraZeneca Plc after having a two bids rejected, as deal-making grips the healthcare industry. Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover. REUTERS/Stefan Wermuth (BRITAIN - Tags: BUSINESS HEALTH)
The logo of AstraZeneca is seen on a medication package in a pharmacy in London April 28, 2014. U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid battle for Britain's AstraZeneca Plc after having a two bids rejected, as deal-making grips the healthcare industry. Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover. REUTERS/Stefan Wermuth (BRITAIN - Tags: BUSINESS HEALTH)
The Hilton hotel 255-269 Pitt Street, Sydney. 27th March, 2012. Photo: Kate Geraghty
The Hilton hotel 255-269 Pitt Street, Sydney. 27th March, 2012. Photo: Kate Geraghty

Sponsoring "educational activities" for doctors is so financially lucrative that pharmaceutical companies are spending upwards of $200,000 on a single event, sparking fresh calls for a ban on industry funding.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Griffith news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.